GlobalData on MSN6d
Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MM
Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...
Daily5d
Sanofi Sarclisa combo gets Japanese nod for newly diagnosed multiple myeloma
Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...
Pharmabiz6d
Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...
pharmaphorum4d
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...
pharmaphorum2d
ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche
Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myeloma, but new data from the ...
Morningstar5d
Sanofi SA ADR SNY
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance5d
Sanofi (SNY)
After hours: February 28 at 5:44:28 PM EST Loading Chart for SNY ...
Yahoo Finance5d
Sanofi (SNY)
After hours: February 28 at 5:44:28 p.m. EST ...